A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)
Public ClinicalTrials.gov record NCT04636801. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 52-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate the efficacy and safety of two doses of CHF6001 (Tanimilast), as add-on to maintenance triple therapy in the target patient population.
Study identification
- NCT ID
- NCT04636801
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 4,710 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 13, 2021
- Primary completion
- Oct 30, 2025
- Completion
- Oct 30, 2025
- Last update posted
- Dec 16, 2025
2021 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Chiesi Clinical Trial - Site 840402 | Sheffield | Alabama | 35660-4020 | — |
| Chiesi Clinical Trial - Site 840480 | Northridge | California | 91324-6200 | — |
| Chiesi Clinical Trial - Site 840487 | Cutler Bay | Florida | 33189-1230 | — |
| Chiesi Clinical Trial - Site 840404 | Hollywood | Florida | 33021 | — |
| Chiesi Clinical Trial - Site 840407 | Miami | Florida | 33144-2100 | — |
| Chiesi Clinical Trial - Site 840444 | Miami | Florida | 33144 | — |
| Chiesi Clinical Trial - Site 840437 | Miami | Florida | 33165-2075 | — |
| Chiesi Clinical Trial - Site 840403 | Miami | Florida | 33175-3598 | — |
| Chiesi Clinical Trial - Site 840463 | Orlando | Florida | 32822-5806 | — |
| Chiesi Clinical Trial - Site 840401 | Peachtree Corners | Georgia | 30071-2656 | — |
| Chiesi Clinical Trial - Site 840478 | New Windsor | New York | 12553-7754 | — |
| Chiesi Clinical Trial - Site 840483 | Philadelphia | Pennsylvania | 19140 | — |
| Chiesi Clinical Trial - Site 840474 | Kerrville | Texas | 78028-9640 | — |
| Chiesi Clinical Trial - Site 840409 | Plano | Texas | 75025 | — |
| Chiesi Clinical Trial - Site 840481 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 432 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04636801, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2025 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04636801 live on ClinicalTrials.gov.